Local News

• Johnson & Johnson extends tender offer for Mentor Corporation  Johnson & Johnson announced it has extended its previously announced cash tender offer, through its wholly owned subsidiary, Maple Merger Sub, for all outstanding shares of common stock of Mentor Corporation until 5:00 p.m. (Eastern time), on January 16, 2009, unless further extended.
  Johnson & Johnson January 06, 2009  
• Monsanto announces yield gains with Deltapine Class Of 09  Monsanto Company announced its D&PL business will market five new varieties as the Deltapine Class of 09 for the coming production season. These varieties were introduced during the 2009 Beltwide Cotton Conferences that have brought the cotton industry together in San Antonio.
  Monsanto Company January 06, 2009  
• Abbott completes acquisition of Ibis Biosciences, a subsidiary of Isis  Isis Pharmaceuticals and Abbott announced that Abbott has completed its purchase of Ibis Biosciences, an Isis subsidiary, for a closing purchase price of $175 million.
  Isis Pharmaceuticals, Inc. January 06, 2009  
• MedImmune submits Marketing Authorisation Application in EU for intranasal flu vaccine  MedImmune, the global biologics unit of AstraZeneca, announced that it has submitted a Marketing Authorisation Application (MAA) for its nasal spray live attenuated influenza vaccine (LAIV), which is now being reviewed by the European Medicines Agency (EMEA).
  AstraZeneca January 06, 2009  
• Dick Bond leaving Tyson Foods  Dick Bond, president and chief executive officer of Tyson Foods, announced he is leaving the company, effective immediately. Leland Tollett, former chairman and CEO of the company, has agreed to return to the company as President and CEO on an interim basis.
  Tyson Foods, Inc. January 05, 2009  
• PPD enters into strategic collaboration with Merck  PPD announced it has entered into a strategic collaboration with Merck & Co. involving vaccine testing and assay development. Under the agreements, PPD purchased Merck's 130,000 square-foot vaccine testing laboratory and related equipment in Wayne, Penn.
  PPD, Inc. January 05, 2009  
• Phase III begins for GAMMAGARD LIQUID plus rHuPH20 in primary immunodeficiency patients  Baxter International and Halozyme Therapeutics announced the start of a Phase III clinical trial of Baxter's GAMMAGARD LIQUID 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme for the treatment of primary immunodeficiency (PID).
  Halozyme Therapeutics, Inc. January 05, 2009  
• Grand Rapids looks to diversify into health care, life sciences  In a state grasping for answers about its future, Michigan's second-largest city may provide some important clues. Along a hilly stretch of downtown Grand Rapids dubbed the Medical Mile, a new economic engine is gradually taking shape.
  Detroit Free Press January 04, 2009  Katherine Yung
• FDA Cardio Renal Advisory Committee to review Daiichi Sankyo, Lilly drug prasugrel  Daiichi Sankyo Company and Eli Lilly and Company confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will review prasugrel during an advisory committee hearing on February 3, 2009.
  Eli Lilly and Company December 31, 2008  
• Johnson & Johnson completes acquisition of Omrix Biopharmaceuticals  Johnson & Johnson announced the completion of its previously announced acquisition of Omrix Biopharmaceuticals, a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products.
  Johnson & Johnson December 30, 2008  

   (next 10 articles)